Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 7,359 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NERVES Clear all
Completed Not applicable Interventional

In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis

NCT00785369
View directory record Official record
Conditions
Skin Cancer, Melanoma, Lentigo Maligna
Interventions
Reflectance confocal microscopy
Device
Lead sponsor
Lucid, Inc.
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Loma Linda, California • Plantation, Florida • Hauppauge, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 27, 2026, 7:33 AM EDT
Active, not recruiting Phase 1 Interventional

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

NCT04930783
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
CDX-301, NEOVAX, Nivolumab, Pembrolizumab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 27, 2026, 7:33 AM EDT
Recruiting Phase 3 Interventional

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
158
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 7:33 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem

NCT01626846
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
John Jay High School
Other
Eligibility
14 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Cross River, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 27, 2026, 7:33 AM EDT
Recruiting No phase listed Observational

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

NCT06222203
View directory record Official record
Conditions
Neurofibromatosis 1, Nerve Sheath Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 120 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 7:33 AM EDT
Not listed Not applicable Interventional

Augmenting Standard-of-care Treatment of Plaque Psoriasis by Neuromodulation

NCT05243303
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Active taVNS, Sham taVNS
Device
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Las Cruces, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 27, 2026, 7:33 AM EDT
Completed Phase 2 Interventional Results available

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

NCT02794883
View directory record Official record
Conditions
Malignant Glioma, Recurrent Glioblastoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Surgical Procedure, Tremelimumab
Biological · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 27, 2026, 7:33 AM EDT
Terminated Phase 1 Interventional

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

NCT01088763
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Gonadotroph Adenoma, Pituitary Basophilic Adenoma, Pituitary Chromophobe Adenoma, Pituitary Eosinophilic Adenoma, Prolactin Secreting Adenoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Pituitary Tumor, Recurrent/Refractory Childhood Hodgkin Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, TSH Secreting Adenoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study, dexamethasone
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 27, 2026, 7:33 AM EDT
Completed Phase 1 Interventional

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

NCT01106508
View directory record Official record
Conditions
Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, Locally Advanced or Metastatic Basal Cell Carcinoma
Interventions
LEQ506
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 27, 2026, 7:33 AM EDT
Completed Phase 2 Interventional Results available

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

NCT00823797
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Bendamustine Hydrochloride, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 27, 2026, 7:33 AM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

NCT01814813
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
Interventions
HSPPC-96, bevacizumab
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
417
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 268 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 27, 2026, 7:33 AM EDT
Terminated Phase 1Phase 2 Interventional

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

NCT00945269
View directory record Official record
Conditions
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, polymerase chain reaction
Biological · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 27, 2026, 7:33 AM EDT
Not listed Phase 4 Interventional

High Versus Low Adductor Canal Block

NCT04155983
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Ropivacaine
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 27, 2026, 7:33 AM EDT
Active, not recruiting Phase 3 Interventional

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

NCT02685605
View directory record Official record
Conditions
Glioblastoma
Interventions
Standard surgery, Intraoperative radiotherapy, Radiochemotherapy, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
Universitätsmedizin Mannheim
Other
Eligibility
18 Years to 80 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Maywood, Illinois • Lake Success, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 27, 2026, 7:33 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00639639
View directory record Official record
Conditions
Malignant Neoplasms of Brain
Interventions
tetanus toxoid, therapeutic autologous dendritic cells, therapeutic autologous lymphocytes
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 27, 2026, 7:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes of Intra-operative IV Tylenol and/or IV Toradol for Carpal Tunnel and Distal Radius Fracture Surgeries

NCT02313675
View directory record Official record
Conditions
Postoperative Pain, Carpal Tunnel Release, Distal Radius Fracture
Interventions
Acetaminophen, Ketorolac Tromethamine, Saline
Drug
Lead sponsor
John Fowler
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 27, 2026, 7:33 AM EDT
Recruiting Phase 1 Interventional

Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau

NCT06639503
View directory record Official record
Conditions
Tibial Plateau Fractures
Interventions
Bupivacain
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 27, 2026, 7:33 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

NCT01250470
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma, Recurrent Brain Neoplasm
Interventions
Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim
Other · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 27, 2026, 7:33 AM EDT
Completed Phase 4 Interventional Results available

Analgesic Benefits of Perineural Versus Intravenous Dexamethasone in Patients Receiving Sciatic Nerve Block

NCT01616173
View directory record Official record
Conditions
Fracture of Ankle
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 27, 2026, 7:33 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

NCT02858869
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
Interventions
Pembrolizumab, Stereotactic Radiosurgery
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 27, 2026, 7:33 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and EDP1503 in Advanced Melanoma

NCT03595683
View directory record Official record
Conditions
Melanoma (Skin), Melanoma
Interventions
Pembrolizumab, EDP1503
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 27, 2026, 7:33 AM EDT
Recruiting No phase listed Observational

Nerve Transfers Plus Electrical Stimulation to Improve Hand Function in Cervical Spinal Cord Injury

NCT06541041
View directory record Official record
Conditions
Cervical Spinal Cord Injury, Cervical Spinal Cord Paralysis, Tetraplegia, Tetraplegia/Tetraparesis, Tetraplegic Spinal Paralysis
Interventions
Brief intraoperative electrical stimulation, Temporary Postoperative Peripheral Nerve Stimulation
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 27, 2026, 7:33 AM EDT
Completed Not applicable Interventional

Geranium Oil and Its Components for the Relief of Numbness-OB 100

NCT01022437
View directory record Official record
Conditions
Nerve Conduction, Numbness
Interventions
Geranium Oil with component PN-34
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 27, 2026, 7:33 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas

NCT00036569
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
adjuvant therapy, pegylated interferon alfa
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 27, 2026, 7:33 AM EDT